Interní Med. 2007; 9(3): 137-140

Rosiglitazon a jeho klinický efekt: studie ADOPT

MUDr. Zuzana Vlasáková CSc
Centrum diabetologie IKEM, Praha

Diabetes mellitus 2. typu je onemocnění, jehož výskyt v poslední době velmi rychle narůstá. Je charakterizované nejen hyperglykemií, ale i dalšími odchylkami, jako je hypertenze, změny v hladinách krevních tuků, parametrů oxidačního stresu, endoteliální dysfunkcí, poruchami v koagulačních činitelích atd. Řada studií dokládá souvislost diabetu a s ním spojených metabolických abnormalit s vyšší celkovou, ale hlavně kardiovaskulární mortalitou (1, 2). Společným patogenním faktorem pro diabetes a kardiovaskulární onemocnění se zdá být inzulinová rezistence (3), která je vedle poruchy sekrece inzulinu hlavní příčinou přechodu porušené glukózové tolerance do plně rozvinutého diabetu s hyperglykemií.

Published: April 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlasáková Z. Rosiglitazon a jeho klinický efekt: studie ADOPT. Interní Med. 2007;9(3):137-140.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovasular mortality. The San Antonio Heart Study. Diab Care 1998; 21: 1167-1172. Go to original source... Go to PubMed...
    2. Morrish NJ, Wang S-L, Fuller JH, Keen H and the WHO multinational study group. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44 (Suppl 2): S14-S21. Go to original source... Go to PubMed...
    3. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. Go to original source... Go to PubMed...
    4. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Maroquin A, Goico J, Ochoa C, Tan S, Berrowitz K, Hodish HN, Azen SP. Preservation of pancreatic ?-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803. Go to original source... Go to PubMed...
    5. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diab Care 2003; 26: 172-178. Go to original source... Go to PubMed...
    6. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin exceretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12. Go to original source... Go to PubMed...
    7. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Feed MI. Effect of rosiglitazone treatment on nontraditonal markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684. Go to original source... Go to PubMed...
    8. Ovalle F, Bell DS. Effect of thiazolidinediones on high-density lipoprotein subfractions. Endocr Pract 2002; 8: 102-104. Go to original source... Go to PubMed...
    9. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diab Care 2000; 23: 557. Go to original source... Go to PubMed...
    10. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The DREAM (Diabetes reduction assessment with ramipril and rosiglitazone medication) trial invesitators. Lancet 2006; 638 (9541): 1096-1105.
    11. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, 0´Neill C, Zinman B, and Viberti G for the ADOPT study group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.